Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Objectives of the study:
1. To verify the safety and the efficacy of the study treatment, defined as the persistent
control of the virus' replication at 48 weeks after the simplification to maraviroc +
darunavir with ritonavir in patients with R5 tropism by viral DNA genotyping.
2. To collect relevant information about the safety, the immunologic and the economic
impact of this strategy.